An Orally Administered Drug Prevents SARS-CoV-2 Replication

Researchers at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue. To evaluate the therapeutic efficacy of EIDD-2801 for COVID-19, the researchers administered EIDD-2801 to human lung tissue (LoM) starting 24 hours or 48 hours post-SARS-CoV-2 exposure and every 12 hours thereafter.

The researchers found that EIDD-2801 led to a more than 25,000-fold reduction in the number of infectious particles in human lung tissue when treatment was initiated 24 hours post-exposure. Virus titers were significantly reduced by 96% when treatment was started 48 hours post-exposure. EIDD-2801 pre-exposure prophylaxis significantly inhibited SARS-CoV-2 replication – reducing virus titers in the human lung tissues of LoM by over 100,000 fold in two independent experiments. Clinical trials for EIDD-2801 are ongoing, and the first results could be released as early as March.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.nature.com/articles/s41586-021-03312-w

#Featured